$LMMY
LAMY

2023 Q2 Form 10-K Financial Statement

#000168316823006240 Filed on September 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 2022 Q2
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $5.033K
YoY Change
% of Gross Profit
Operating Expenses $56.42K
YoY Change
Operating Profit -$56.42K
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$56.42K
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$56.42K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 7.777M shares 5.686M shares
Diluted Shares Outstanding 5.686M shares

Balance Sheet

Concept 2023 Q2 2023 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $7.855K $10.11K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $7.855K $10.11K
YoY Change -22.28%
LONG-TERM ASSETS
Property, Plant & Equipment $9.986K $15.02K
YoY Change -33.51%
Goodwill
YoY Change
Intangibles $19.20K $28.87K
YoY Change -33.48%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $29.19K $43.89K
YoY Change -33.49%
TOTAL ASSETS
Total Short-Term Assets $7.855K $10.11K
Total Long-Term Assets $29.19K $43.89K
Total Assets $37.04K $54.00K
YoY Change -31.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $610.00 $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.610K $0.00
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $62.52K $54.43K
YoY Change 14.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.610K $0.00
Total Long-Term Liabilities $62.52K $54.43K
Total Liabilities $66.13K $54.43K
YoY Change 21.49%
SHAREHOLDERS EQUITY
Retained Earnings -$57.36K -$937.00
YoY Change 6021.45%
Common Stock $778.00 $500.00
YoY Change 55.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$29.09K -$437.00
YoY Change
Total Liabilities & Shareholders Equity $37.04K $54.00K
YoY Change -31.39%

Cashflow Statement

Concept 2023 Q2 2023 2022 Q2
OPERATING ACTIVITIES
Net Income -$56.42K
YoY Change
Depreciation, Depletion And Amortization $5.033K
YoY Change
Cash From Operating Activities -$38.11K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $27.77K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $35.86K
YoY Change
NET CHANGE
Cash From Operating Activities -$38.11K
Cash From Investing Activities $0.00
Cash From Financing Activities $35.86K
Net Change In Cash -$2.252K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$38.11K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-2039216
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Allen Street Unit 10104
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
New York City
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001939937
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-05-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
333-266341
CY2023 dei Entity Registrant Name
EntityRegistrantName
L A M Y
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10002
CY2023 dei City Area Code
CityAreaCode
657
CY2023 dei Local Phone Number
LocalPhoneNumber
315-8312
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7777000 shares
CY2023Q2 dei Entity Public Float
EntityPublicFloat
0 usd
CY2023 dei Auditor Firm
AuditorFirmId
6554
CY2023 dei Auditor Name
AuditorName
Bolko & Company
CY2023 dei Auditor Location
AuditorLocation
Boca Raton, Florida
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7855 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10107 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
7855 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
10107 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19203 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28870 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9986 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15019 usd
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
29189 usd
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
43889 usd
CY2023Q2 us-gaap Assets
Assets
37044 usd
CY2022Q2 us-gaap Assets
Assets
53996 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
610 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 usd
CY2023Q2 LAMY Advances From Related Parties
AdvancesFromRelatedParties
3000 usd
CY2022Q2 LAMY Advances From Related Parties
AdvancesFromRelatedParties
0 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3610 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
0 usd
CY2023Q2 LAMY Loans From Related Parties
LoansFromRelatedParties
18100 usd
CY2022Q2 LAMY Loans From Related Parties
LoansFromRelatedParties
15100 usd
CY2023Q2 LAMY Note Payable Related Party
NotePayableRelatedParty
10000 usd
CY2022Q2 LAMY Note Payable Related Party
NotePayableRelatedParty
10000 usd
CY2023Q2 us-gaap Other Notes Payable
OtherNotesPayable
29000 usd
CY2022Q2 us-gaap Other Notes Payable
OtherNotesPayable
29000 usd
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
5422 usd
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
333 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
62522 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
54433 usd
CY2023Q2 us-gaap Liabilities
Liabilities
66132 usd
CY2022Q2 us-gaap Liabilities
Liabilities
54433 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7777000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7777000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5000000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
778 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
500 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27492 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57358 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-937 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-29088 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-437 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37044 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53996 usd
CY2023 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56421 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
937 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-56421 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-937 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56421 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-937 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-56421 usd
us-gaap Net Income Loss
NetIncomeLoss
-937 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5686257 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5686257 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1630137 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1630137 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
0 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500 usd
us-gaap Net Income Loss
NetIncomeLoss
-937 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-437 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25270 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2500 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-56421 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-29088 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-56421 usd
us-gaap Net Income Loss
NetIncomeLoss
-937 usd
CY2023 us-gaap Depreciation
Depreciation
5033 usd
us-gaap Depreciation
Depreciation
81 usd
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
9667 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
130 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
610 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
CY2023 LAMY Increase In Advances From Related Parties
IncreaseInAdvancesFromRelatedParties
3000 usd
LAMY Increase In Advances From Related Parties
IncreaseInAdvancesFromRelatedParties
0 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38111 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-726 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27770 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
500 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
3000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
10000 usd
CY2023 LAMY Proceeds From Accrued Interest
ProceedsFromAccruedInterest
5089 usd
LAMY Proceeds From Accrued Interest
ProceedsFromAccruedInterest
333 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35859 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10833 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2252 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10107 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10107 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7855 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10107 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023 LAMY Proceeds Of Loan From Related Party In Exchange Of Asset
ProceedsOfLoanFromRelatedPartyInExchangeOfAsset
0 usd
LAMY Proceeds Of Loan From Related Party In Exchange Of Asset
ProceedsOfLoanFromRelatedPartyInExchangeOfAsset
15100 usd
CY2023 LAMY Proceeds From Note Payable Against Acquisition Of Intangibles
ProceedsFromNotePayableAgainstAcquisitionOfIntangibles
0 usd
LAMY Proceeds From Note Payable Against Acquisition Of Intangibles
ProceedsFromNotePayableAgainstAcquisitionOfIntangibles
29000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57358 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zP8nVnPhe7t2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates and Assumptions</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
29000 usd
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
9667 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9797 usd
CY2023 LAMY Property Plant And Equipment Useful Life1
PropertyPlantAndEquipmentUsefulLife1
3 years
CY2022Q2 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
15100 usd
CY2023 us-gaap Depreciation
Depreciation
5033 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5114 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
57358 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7777000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7777000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5000000 shares
CY2023Q2 LAMY Long Term Debt Maturities Repayments Of Principal Remaining Current Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainingCurrentYear
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
29000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
0 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12045 usd
CY2023 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
12045 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12045 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12045 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd

Files In Submission

Name View Source Status
0001683168-23-006240-index-headers.html Edgar Link pending
0001683168-23-006240-index.html Edgar Link pending
0001683168-23-006240.txt Edgar Link pending
0001683168-23-006240-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
lamy-20230531.xsd Edgar Link pending
lamy_ex2301.htm Edgar Link pending
lamy_ex3101.htm Edgar Link pending
lamy_ex3102.htm Edgar Link pending
lamy-20230531_pre.xml Edgar Link unprocessable
lamy-20230531_lab.xml Edgar Link unprocessable
lamy-20230531_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
lamy-20230531_cal.xml Edgar Link unprocessable
lamy_ex3201.htm Edgar Link pending
lamy_i10k-053123.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lamy_i10k-053123_htm.xml Edgar Link completed